Each brokerage/analyst has given ATNM a target significantly higher than this NYSE American past champ closed this past Friday.
At the tippy top, according to MarketBeat, is an HC Wainwright target of $53.00.
From this past Friday's close, that provides ATNM with an incredible upside potential in the neighborhood of 285%.
After Saturday's huge "positive results" announcement, could some of these analysts upgrade their targets in the near term?
No. 4 ATNM Potential Catalyst - New Partnership With The NCI Could Prove Extremely Fruitful Long Term
Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Leukemia and Other Hematologic Malignancies
- National Cancer Institute will sponsor and oversee clinical trials of Actimab-A under the terms of the Cooperative Research and Development Agreement
- Collaboration will provide Actimab-A and other necessary support to study Actimab-A alone or in combinations with chemotherapy, immunotherapy and/or targeted agents aligned with Actinium's development strategy
- Over 2,000 institutions within NCI funded extramural clinical networks will have access to Actimab-A for conducting clinical and non-clinical research and development
- CRADA Clinical Studies will be performed utilizing NCI's Experimental Therapeutics Clinical Trials Network (ETCTN) and National Clinical Trials Network (NCTN)
NEW YORK, Feb. 6, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes for Health (NIH), to develop Actimab-A for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. Under the terms of the CRADA, the NCI will serve as the regulatory sponsor for any clinical trials mutually approved by both parties to study Actimab-A while Actinium will be responsible for supplying and distributing Actimab-A to participating clinical sites and providing additional support as needed. The CRADA will provide broad support for the development of Actimab-A alone or in combination with chemotherapy, immunotherapy, targeted agents and other novel combinations, in line with Actinium's strategy of leveraging Actimab-A's targeted radiotherapy mechanism to elicit synergistic effects.
Read the full article here.
No. 5 ATNM Potential Catalyst - Low Float Volatility Possible On Daily Basis
According to the Yahoo Finance website, ATNM has a low float.
The website reports this profile to have approximately 24.47Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could more 2023 positive company news help provide a near term spark?
ATNM Recap - 5 Potential Catalysts Could Provide A Near Term Breakout Spark
No. 1 - Could Saturday's "Positive Results" Announcement Fuel ATNM To A Near Term Breakout?
No. 2 - Bullish Triggered Technicals Galore
No. 3 - ATNM Has Strong Analyst Coverage Including A Massive HC Wainwright $53 Target
No. 4 - New Partnership With The NCI Could Prove Extremely Fruitful Long Term
No. 5 - Low Float Volatility Possible On Daily Basis
Coverage is officially reinitiated on ATNM. When time permits, do this: